566.80

1.67% -9.6647

Thermo Fisher Scientific Inc (TMO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TMO Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$576.46

Aprire:

$567.37

Volume 24 ore:

630.31K

Relative Volume:

0.27

Capitalizzazione di mercato:

$210.59B

Reddito:

$45.20B

Utile/perdita netta:

$6.87B

Rapporto P/E:

31.16

EPS:

18.1888

Flusso di cassa netto:

$6.75B

1 W Prestazione:

-0.96%

1M Prestazione:

+13.06%

6M Prestazione:

-2.04%

1 anno Prestazione:

+18.76%

Intervallo 1D:

$560.42

$571.09

Intervallo di 1 settimana:

$555.91

$588.56

Portata 52W:

$435.27

$643.99

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Nome

Thermo Fisher Scientific Inc

Settore

Healthcare (1080)

Industria

Diagnostics & Research (49)

Telefono

(781) 622-1000

Indirizzo

168 THIRD AVENUE, WALTHAM, MA

Dipendente

125,000

Cinguettio

@thermofisher

Prossima data di guadagno

2026-07-23

Ultimi documenti SEC

TMO's Discussions on Twitter

Compare TMO vs DHR, IDXX, IQV, A

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TMO Thermo Fisher Scientific Inc	566.68	207.93B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	195.95	138.14B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	557.95	43.87B	4.45B	1.10B	1.06B	13.59
IQV Iqvia Holdings Inc	237.70	35.59B	16.63B	1.39B	2.12B	8.0674
A Agilent Technologies Inc	138.40	38.94B	7.23B	1.41B	1.09B	4.979

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-27	Iniziato	DZ Bank	Buy
2025-12-11	Aggiornamento	Citigroup	Neutral → Buy
2025-12-09	Iniziato	Goldman	Buy
2025-12-08	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2025-12-02	Ripresa	Morgan Stanley	Overweight
2025-12-01	Aggiornamento	HSBC Securities	Hold → Buy
2025-09-11	Aggiornamento	Barclays	Equal Weight → Overweight
2025-08-19	Iniziato	William Blair	Outperform
2025-07-24	Downgrade	HSBC Securities	Buy → Hold
2025-07-11	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-07-09	Downgrade	UBS	Buy → Neutral
2025-01-10	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-12-23	Iniziato	Scotiabank	Sector Perform
2024-10-14	Iniziato	Redburn Atlantic	Buy
2024-10-01	Iniziato	Stephens	Overweight
2024-08-28	Iniziato	Wells Fargo	Overweight
2024-06-03	Ripresa	Jefferies	Buy
2024-03-18	Ripresa	Citigroup	Neutral
2024-01-24	Downgrade	Barclays	Overweight → Equal Weight
2024-01-08	Downgrade	Bernstein	Outperform → Mkt Perform
2023-12-18	Iniziato	HSBC Securities	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-10-26	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
2023-10-25	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2023-09-28	Iniziato	Bernstein	Outperform
2023-09-06	Ripresa	Citigroup	Buy
2023-07-19	Iniziato	Raymond James	Outperform
2023-07-19	Reiterato	Robert W. Baird	Outperform
2023-07-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2023-04-04	Reiterato	Barclays	Overweight
2022-12-14	Iniziato	Deutsche Bank	Buy
2022-12-07	Iniziato	RBC Capital Mkts	Outperform
2022-10-27	Downgrade	The Benchmark Company	Buy → Hold
2022-08-25	Iniziato	Credit Suisse	Neutral
2022-04-25	Downgrade	Wells Fargo	Equal Weight → Underweight
2022-01-26	Ripresa	Barclays	Overweight
2021-10-20	Aggiornamento	Citigroup	Neutral → Buy
2021-10-15	Ripresa	Cowen	Outperform
2021-08-05	Ripresa	Credit Suisse	Outperform
2021-07-16	Iniziato	The Benchmark Company	Buy
2021-03-18	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2021-03-03	Iniziato	Barclays	Overweight
2021-01-08	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-12-02	Iniziato	Goldman	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Sector Weight
2020-09-30	Iniziato	Atlantic Equities	Overweight
2020-09-14	Iniziato	Morgan Stanley	Overweight
2020-08-20	Ripresa	JP Morgan	Overweight
2020-07-15	Aggiornamento	Cleveland Research	Neutral → Buy
2020-07-07	Reiterato	Needham	Buy
2020-04-23	Reiterato	Needham	Buy
2020-01-31	Reiterato	Needham	Buy
2020-01-22	Iniziato	Credit Suisse	Neutral
2020-01-08	Iniziato	Wells Fargo	Equal Weight
2020-01-07	Iniziato	Citigroup	Buy
2019-11-15	Iniziato	Stifel	Buy
2019-07-25	Reiterato	Needham	Buy
2019-07-16	Downgrade	Needham	Strong Buy → Buy
2019-05-30	Iniziato	Wolfe Research	Outperform
2019-05-23	Reiterato	Needham	Strong Buy
2019-04-22	Reiterato	Needham	Strong Buy
2019-04-16	Reiterato	BofA/Merrill	Buy

Mostra tutto

Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie

Jul 28, 2026

Flow Cytometry Diagnostics Market Set to Reach USD 3.5 Billion by 2036 Driven by MRD Testing and Multiparametric Analysis | Sysmex Corporation, Thermo Fisher Scientific Inc. - 24-7 Press Release Newswire

Jul 28, 2026

Jul 27, 2026

Form 144 THERMO FISHER SCIENTIFIC INC. For: 27 July By Investing.com - Investing.com India

Jul 27, 2026

Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma

Jul 27, 2026

Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch

Jul 27, 2026

TMO Maintained by Piper Sandler -- Price Target Raised to $600 - GuruFocus

Jul 27, 2026

Thermo Fisher (TMO) insider files to sell 400 common shares valued at $226,000 - Stock Titan

Jul 27, 2026

Piper Sandler Adjusts Price Target on Thermo Fisher Scientific to $600 From $510, Maintains Neutral Rating - marketscreener.com

Jul 27, 2026

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 - Yahoo Finance

Jul 27, 2026

Thermo Fisher stock holds on steady earnings base - Ad-hoc-news.de

Jul 27, 2026

THERMO FISHER SCIENTIFIC INC : PIPER SANDLER RAISES TARGET PRICE TO $600 FROM $510 - Bitget

Jul 27, 2026

Jul 25, 2026

Thermo Fisher Scientific (NYSE:TMO) Faces A Margin Test - Kalkine Media

Jul 25, 2026

Thermo Fisher Scientific Q2 up 10% to USD 11.99 billion - Medical Buyer

Jul 25, 2026

Thermo Fisher stock trades steadily as diagnostics and biopharma demand support earnings trajectory - AD HOC NEWS

Jul 25, 2026